A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?
1
VIENNA HEALTH BOARD and L. B. Institute of Clinical Neurobiology, Vienna, Austria
|
2
3
Institute of Applied Microbiology, University of Agriculture, Vienna, Austria
|
4
ALTEGEN Inc, Hamburg, Federal Republic of Germany
|
Publication type: Book Chapter
Publication date: 2002-01-01
SJR: —
CiteScore: —
Impact factor: —
ISSN: 03036995
PubMed ID:
12456054
Abstract
Recently, a novel risk gene protein expressed in elderly patientswith the diagnosis of Alzheimer disease (AD) was discovered on chromosome 21 within the APP (amyloid precursor protein) region. This 79 amino acidprotein, ALZAS (Alzheimer Associated Protein) contains the β-amyloid peptide 1–42 fragment, the APP transmembrane signal, and a unique 12 aminoacid c-terminal which is not present in any known allele of the APP gene.Reverse transcription-peR revealed that the transcript of ALZAS was ex-pressed in cortical and hippocampal regions of human Alzheimer diseasebrain as well as in leukocytes derived from AD patients. Most specifically, anendogenous antibody was found in patients with confirmed AD, in patientswith depression, and in subjects suggested to have presymptomatic AD,where it was directed against epitopes within the intron encoded amino acidc-terminal sequence.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
|
|
|
Recent Patents on Biotechnology
1 publication, 16.67%
|
|
|
Therapeutic Advances in Neurological Disorders
1 publication, 16.67%
|
|
|
Journal of Molecular Neuroscience
1 publication, 16.67%
|
|
|
Journal of Cellular and Molecular Medicine
1 publication, 16.67%
|
|
|
Expert Review of Molecular Diagnostics
1 publication, 16.67%
|
|
|
1
|
Publishers
|
1
|
|
|
Bentham Science Publishers Ltd.
1 publication, 16.67%
|
|
|
SAGE
1 publication, 16.67%
|
|
|
Springer Nature
1 publication, 16.67%
|
|
|
Wiley
1 publication, 16.67%
|
|
|
Taylor & Francis
1 publication, 16.67%
|
|
|
1
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
6
Total citations:
6
Citations from 2024:
0
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Kienzl E. et al. A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker? // Advances in Down Syndrome Research. 2002. Vol. 62. pp. 87-95.
GOST all authors (up to 50)
Copy
Kienzl E., Jellinger K., Janetzky B., Steindl H., Bergmann J. A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker? // Advances in Down Syndrome Research. 2002. Vol. 62. pp. 87-95.
Cite this
RIS
Copy
TY - GENERIC
DO - 10.1007/978-3-7091-6139-5_9
UR - https://doi.org/10.1007/978-3-7091-6139-5_9
TI - A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?
T2 - Advances in Down Syndrome Research
AU - Kienzl, E.
AU - Jellinger, K.
AU - Janetzky, B.
AU - Steindl, H.
AU - Bergmann, J.
PY - 2002
DA - 2002/01/01
PB - Springer Nature
SP - 87-95
IS - 62
PMID - 12456054
SN - 0303-6995
ER -
Cite this
BibTex (up to 50 authors)
Copy
@incollection{2002_Kienzl,
author = {E. Kienzl and K. Jellinger and B. Janetzky and H. Steindl and J. Bergmann},
title = {A broader horizon of Alzheimer pathogenesis: ALZAS — an early serum biomarker?},
publisher = {Springer Nature},
year = {2002},
number = {62},
pages = {87--95},
month = {jan}
}